Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 500 1556

Website: gaintherapeutics.com

Address:

4800 Montgomery Lane, Suite 220, Bethesda, United States

microcapspeculator Jul. 12 at 5:23 PM

$GANX I like the timing of this years M.J. Fox Foundation meeting on October 16th. Gain is also listed as a sponsor.

0 · Reply

microcapspeculator Jul. 12 at 2:53 PM

$GANX Seems like Lysomal function is the key. One of the reasons I think a buy out happens is this recent Gain article. Right behind GT-02287 is GT-02329. You are going to want both. Unlocking Lysosome Secrets: Insights from Monther Abu-Remaileh https://www.eurekamagazine.co.uk/content/news/unlocking-lysosome-secrets-insights-from-monther-abu-remaileh/ Allosteric Modulation of GCase Enhances Lysosomal Activity and Reduces ER Stress in GCase-Related Disorders - PMC https://share.google/2B7fqhDnVGGcO7sBf Treatment with GT-02287 and GT-02329 improved the folding of mutant GCase, protected the GCaseLeu444Pro variant from degradation, and facilitated the delivery of active GCase to lysosomes. This enhanced lysosomal function and reduced cellular stress. These findings validate the STARs’ mechanism of action and highlight their therapeutic potential for GCase-related disorders, including GD, PD, and Dementia with Lewy Bodies.

0 · Reply

Apiker Jul. 11 at 7:59 PM

$GANX one can dream!

1 · Reply

mwb1 Jul. 11 at 7:55 PM

$GANX Just a reminder, it was not just one clinician who requested an enrollment extension. It was "multiple clinicians, as well as additional patients". Also, in my correspondence with Apaar, regarding the patients who might have a gap in between dosing from the end of the original 90 days and the beginning of the new extended dosing window, he mentioned how it "could provide further insight on how the drug works given they will have a washout period compared to patients who will not have a gap in dosing" as @microcapspeculator had mentioned. Small detail: notice that he said "how" the drug works, not "if" it works. I think it is safe to say that the Gain team is confident that 02287works. It is a question of exactly how and to what extent.

2 · Reply

cleverscreenname Jul. 11 at 4:40 PM

$GANX added

0 · Reply

yololambo Jul. 11 at 2:34 PM

$GANX Anybody watching what’s happening with $INKT? They showed one patient in remission from testicular cancer and it’s more than 5x-ing already today. Not saying that will be us but it is a good reminder of how dramatically the market can react on biotech news.

1 · Reply

Jwa68 Jul. 11 at 5:21 AM

$GANX $PRVB

2 · Reply

microcapspeculator Jul. 10 at 8:38 PM

$GANX This is a new section they just put into the July investor deck. Highlighting the IP.

0 · Reply

ZackInvest008 Jul. 10 at 6:54 PM

$GANX How is this company funding operations? Looks like 20M a year cash burn with less than half a year on the books. Talks of milestone payments later this year. Can they make it?

2 · Reply

Trade82 Jul. 10 at 5:10 PM

$GANX new july updated presentation on website with known upcoming milestones

0 · Reply

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 10, 2025, 8:00 AM EDT - 4 weeks ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 8:45 AM EDT - 6 weeks ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 14, 2025, 7:30 AM EDT - 2 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 7:30 AM EDT - 2 months ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 1, 2025, 7:30 AM EDT - 2 months ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 7:45 AM EDT - 2 months ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Mar 28, 2025, 8:30 AM EDT - 3 months ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 27, 2025, 7:00 AM EDT - 3 months ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 14, 2025, 7:45 AM EDT - 4 months ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 6, 2025, 7:55 AM EST - 4 months ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Feb 6, 2025, 8:45 AM EST - 5 months ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 5, 2025, 8:30 AM EST - 5 months ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Dec 31, 2024, 12:23 PM EST - 6 months ago

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Dec 23, 2024, 7:30 AM EST - 7 months ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 7 months ago

Gain Therapeutics To Present At Biotech Showcase 2025

Oct 7, 2024, 7:00 AM EDT - 9 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 10 months ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 10 months ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 10 months ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 10 months ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 11 months ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jun 28, 2024, 4:39 PM EDT - 1 year ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 8:35 AM EDT - 1 year ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 13, 2024, 9:00 PM EDT - 1 year ago

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

Jun 13, 2024, 4:44 PM EDT - 1 year ago

Gain Therapeutics Announces Proposed Public Offering

May 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 29, 2024, 6:15 PM EDT - 1 year ago

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 14, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Apr 24, 2024, 9:25 AM EDT - 1 year ago

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease

Apr 8, 2024, 9:25 AM EDT - 1 year ago

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Apr 1, 2024, 9:25 AM EDT - 1 year ago

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Mar 15, 2024, 2:30 PM EDT - 1 year ago

Gain Therapeutics to Present at Public Ventures Discovery Day

Mar 5, 2024, 8:00 AM EST - 1 year ago

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease

Feb 27, 2024, 2:00 PM EST - 1 year ago

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

Feb 14, 2024, 12:29 PM EST - 1 year ago

Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

Feb 6, 2024, 9:56 AM EST - 1 year ago

UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

Jan 12, 2024, 6:49 PM EST - 1 year ago

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Jan 2, 2024, 8:00 AM EST - 1 year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Dec 22, 2023, 5:56 PM EST - 1 year ago

Doubling Down On Gain Therapeutics

Dec 1, 2023, 8:00 AM EST - 1 year ago

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Nov 29, 2023, 8:00 AM EST - 1 year ago

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

Nov 24, 2023, 1:01 PM EST - 1 year ago

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

Nov 21, 2023, 8:54 AM EST - 1 year ago

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

microcapspeculator Jul. 12 at 5:23 PM

$GANX I like the timing of this years M.J. Fox Foundation meeting on October 16th. Gain is also listed as a sponsor.

0 · Reply

microcapspeculator Jul. 12 at 2:53 PM

0 · Reply

Apiker Jul. 11 at 7:59 PM

$GANX one can dream!

1 · Reply

mwb1 Jul. 11 at 7:55 PM

2 · Reply

cleverscreenname Jul. 11 at 4:40 PM

$GANX added

0 · Reply

yololambo Jul. 11 at 2:34 PM

1 · Reply

Jwa68 Jul. 11 at 5:21 AM

$GANX $PRVB

2 · Reply

microcapspeculator Jul. 10 at 8:38 PM

$GANX This is a new section they just put into the July investor deck. Highlighting the IP.

0 · Reply

ZackInvest008 Jul. 10 at 6:54 PM

$GANX How is this company funding operations? Looks like 20M a year cash burn with less than half a year on the books. Talks of milestone payments later this year. Can they make it?

2 · Reply

Trade82 Jul. 10 at 5:10 PM

$GANX new july updated presentation on website with known upcoming milestones

0 · Reply

microcapspeculator Jul. 10 at 4:00 PM

$GANX This Abbvie deal pays $700M upfront for a phase 1 with good initial data. Part of that is a 79% response rate. A different market but I think everyone in trial will see a GCase improvement with GT-02287. AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B - BioSpac https://www.biospace.com/deals/abbvie-scoops-up-ichnos-glenmarks-lead-myeloma-antibody-for-nearly-2b

1 · Reply

Jwa68 Jul. 10 at 1:33 PM

$GANX 50k bid. Nice.

2 · Reply

microcapspeculator Jul. 10 at 1:28 PM

$GANX Havent seen that big of bid to start the day in a long time.

0 · Reply

Jwa68 Jul. 10 at 12:58 PM

$GANX Resolutely

0 · Reply

BenGraham777 Jul. 10 at 1:15 AM

$GANX X-bagger.

1 · Reply

microcapspeculator Jul. 9 at 3:36 PM

$GANX Good news on nausea if only 1 out of first 11 had any issue. As we have suspected fixing issue with misfolding is not going to cause off target issues. Gain Therapeutics(GANX): Scotiabank 7/8/25 Note with Target of $12: Positive Vibes Post NDR with GANX https://gaintherapeutics.wordpress.com/2025/07/09/gain-therapeuticsganx-scotiabank-7-8-25-note-with-target-of-12-positive-vibes-post-ndr-with-ganx/

0 · Reply

Apiker Jul. 9 at 2:44 PM

$GANX looks like algorithms. Hits the 20 ema and sells off

0 · Reply

microcapspeculator Jul. 9 at 12:55 PM

$GANX Scotiabank put out another update after last weeks meetings.

2 · Reply

john_Ennis Jul. 9 at 12:17 PM

$GANX I know that November is not far away but as big pharma are waiting for full data before jumping in then are we to expect a quiet few months of just drifting with the tide of the overall market without any catalysts to keep us inflated ? If so then maybe we have time to put some funds to use elsewhere. Dangerous strategy ?

2 · Reply

Gandalf01 Jul. 8 at 11:06 PM

$GANX So, just having taken a huge loss in $INMB with the failure of their Alzheimer's drug I emailed Gain Therapeutics asking how soon they might try a phase one for Alzheimer's. There are no frontrunners for this devastating disease just like Parkinson's. I know their current phase one is focused on PD right now but the mechanism of action of 2287 seems like a perfect fit for AD also. Ran it through the AI bots and they agreed that g case was significantly involved in the formation of Alzheimer's. Gain's 2287 for AD is in the Gain Therapeutics pipeline, I would like to see them push this along since phase 1's are not that expensive, why not have two running at the same time? PD & AD with 2287, and I think they even have a stronger version try that one for AD. I will let you know the response to my email.

2 · Reply

Markus_Montag Jul. 8 at 8:34 PM

$GANX The big peril is to get emotionally involved. This is when you make mistakes and fall into the trap of bio-grifters. Nothing is certain but things can change in an instant, not only on the upside though. My point here is what younger folks would call avoiding to having a bag holder mentality. Being emotional with your investments make you prone to always find excuses to believe one more day and to discard bad news. I am completely detached to all of it, not only because I have significant wealth but because I went through such dire straits that I have totally dissociated outside noises from my decisions.

5 · Reply

marvessa Jul. 8 at 3:02 PM

$GANX November will be our month

0 · Reply

Market Cap	53.00M
Revenue (ttm)	0.00
Net Income (ttm)	-20.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.07

Volume	238,000
Avg Vol	286,854
Day's Range	N/A - N/A
Shares Out	29.95M
Stochastic %K	43%
Beta	0.12
Analysts	Strong Sell
Price Target	$8.00